Limits...
A hospital cost analysis of a fibrin sealant patch in soft tissue and hepatic surgical bleeding

View Article: PubMed Central - PubMed

ABSTRACT

Background: Despite hemostat use, uncontrolled surgical bleeding is prevalent. Drawbacks of current hemostats include limitations with efficacy on first attempt and suboptimal ease-of-use. Evarrest® is a novel fibrin sealant patch that has demonstrated high hemostatic efficacy compared with standard of care across bleeding severities. The objective of this study was to conduct a hospital cost analysis of the fibrin sealant patch versus standard of care in soft tissue and hepatic surgical bleeding.

Methods: The analysis quantified the 30-day costs of each comparator from a hospital perspective. Published US unit costs were applied to resource use (ie, initial treatment, retreatment, operating time, hospitalization, transfusion, and ventilator) reported in four trials. A “surgical” analysis included resources clinically related to the hemostatic benefit of the fibrin sealant patch, whereas a “hospital” analysis included all resources reported in the trials. An exploratory subgroup analysis focused solely on coagulopathic patients defined by abnormal blood test results.

Results: The surgical analysis predicted cost savings of $54 per patient with the fibrin sealant patch compared with standard of care (net cost impact: −$54 per patient; sensitivity range: −$1,320 to $1,213). The hospital analysis predicted further cost savings with the fibrin sealant patch (net cost impact of −$2,846 per patient; sensitivity range: −$1,483 to −$5,575). Subgroup analyses suggest that the fibrin sealant patch may provide dramatic cost savings in the coagulopathic subgroup of $3,233 (surgical) and $9,287 (hospital) per patient. Results were most sensitive to operating time and product units.

Conclusion: In soft tissue and hepatic problematic surgical bleeding, the fibrin sealant patch may result in important hospital cost savings.

No MeSH data available.


Related in: MedlinePlus

Resource savings and net cost impact of the fibrin sealant patch compared with SoC.Note: Results are shown for combined soft tissue and hepatic bleeding for (A) overall population (surgical analysis), (B) overall population (hospital analysis), (C) coagulopathic patients (surgical analysis), and (D) coagulopathic patients (hospital analysis).Abbreviation: SoC, standard of care.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC5036832&req=5

f1-ceor-8-507: Resource savings and net cost impact of the fibrin sealant patch compared with SoC.Note: Results are shown for combined soft tissue and hepatic bleeding for (A) overall population (surgical analysis), (B) overall population (hospital analysis), (C) coagulopathic patients (surgical analysis), and (D) coagulopathic patients (hospital analysis).Abbreviation: SoC, standard of care.

Mentions: The cost analysis predicted that the fibrin sealant patch compared with SoC is a cost-saving strategy for hospitals when used in soft tissue and hepatic surgical bleeding (Figure 1A and B; Table 3). The fibrin sealant patch was predicted to result in cost savings of $54 and $2,846 per patient, for the surgical and hospital analyses, respectively. Costed resource utilization was lower with the fibrin sealant patch compared with SoC for the majority of resources collected across all four trials (Table 3).


A hospital cost analysis of a fibrin sealant patch in soft tissue and hepatic surgical bleeding
Resource savings and net cost impact of the fibrin sealant patch compared with SoC.Note: Results are shown for combined soft tissue and hepatic bleeding for (A) overall population (surgical analysis), (B) overall population (hospital analysis), (C) coagulopathic patients (surgical analysis), and (D) coagulopathic patients (hospital analysis).Abbreviation: SoC, standard of care.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC5036832&req=5

f1-ceor-8-507: Resource savings and net cost impact of the fibrin sealant patch compared with SoC.Note: Results are shown for combined soft tissue and hepatic bleeding for (A) overall population (surgical analysis), (B) overall population (hospital analysis), (C) coagulopathic patients (surgical analysis), and (D) coagulopathic patients (hospital analysis).Abbreviation: SoC, standard of care.
Mentions: The cost analysis predicted that the fibrin sealant patch compared with SoC is a cost-saving strategy for hospitals when used in soft tissue and hepatic surgical bleeding (Figure 1A and B; Table 3). The fibrin sealant patch was predicted to result in cost savings of $54 and $2,846 per patient, for the surgical and hospital analyses, respectively. Costed resource utilization was lower with the fibrin sealant patch compared with SoC for the majority of resources collected across all four trials (Table 3).

View Article: PubMed Central - PubMed

ABSTRACT

Background: Despite hemostat use, uncontrolled surgical bleeding is prevalent. Drawbacks of current hemostats include limitations with efficacy on first attempt and suboptimal ease-of-use. Evarrest® is a novel fibrin sealant patch that has demonstrated high hemostatic efficacy compared with standard of care across bleeding severities. The objective of this study was to conduct a hospital cost analysis of the fibrin sealant patch versus standard of care in soft tissue and hepatic surgical bleeding.

Methods: The analysis quantified the 30-day costs of each comparator from a hospital perspective. Published US unit costs were applied to resource use (ie, initial treatment, retreatment, operating time, hospitalization, transfusion, and ventilator) reported in four trials. A “surgical” analysis included resources clinically related to the hemostatic benefit of the fibrin sealant patch, whereas a “hospital” analysis included all resources reported in the trials. An exploratory subgroup analysis focused solely on coagulopathic patients defined by abnormal blood test results.

Results: The surgical analysis predicted cost savings of $54 per patient with the fibrin sealant patch compared with standard of care (net cost impact: −$54 per patient; sensitivity range: −$1,320 to $1,213). The hospital analysis predicted further cost savings with the fibrin sealant patch (net cost impact of −$2,846 per patient; sensitivity range: −$1,483 to −$5,575). Subgroup analyses suggest that the fibrin sealant patch may provide dramatic cost savings in the coagulopathic subgroup of $3,233 (surgical) and $9,287 (hospital) per patient. Results were most sensitive to operating time and product units.

Conclusion: In soft tissue and hepatic problematic surgical bleeding, the fibrin sealant patch may result in important hospital cost savings.

No MeSH data available.


Related in: MedlinePlus